07:00 , Oct 5, 2009 |  BC Week In Review  |  Company News

Cambridge Biostability, Lipoxen, Health Protection Agency, University of Cambridge infectious news

In June, Cambridge Biostability entered voluntary liquidation. The company's assets included its VitRIS (Vitrified Readily Injectable Suspensions) technology to make thermostable liquid vaccines. As a result of the liquidation, Lipoxen was appointed the lead member...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Cambridge Biostability, Lipoxen preclinical data

In mice, ImuXen from Lipoxen increased the efficacy of influenza vaccines by about 30-fold, and a VitRIS-stablized formulation enhanced efficacy of the vaccine by a further 4-fold. Lipoxen's ImuXen comprises liposome-encapsulated killed influenza virus, and...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Company News

Cambridge Biostability, Lipoxen, Health Protection Agency, University of Cambridge deal

The parties will reformulate vaccines for influenza and undisclosed indications to improve stability, increase shelf-life and reduce dosing. Cambridge Biostability will provide its VitRIS technology to generate thermostable formulations of the vaccines. Lipoxen will provide...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

Cambridge Biostability management update

Cambridge Biostability Ltd. , Cambridge, U.K.   Business: Drug delivery   Hired: Luca Guerzoni as CEO, formerly an independent consultant; he replaces David Stone, who will remain a non-executive director  ...
07:00 , Jun 4, 2007 |  BC Week In Review  |  Company News

Ace BioSciences, Cambridge Biostability deal

Ace received an exclusive, worldwide license to Cambridge Biostability's HolaVax-ETEC vaccine , which will be renamed ACE537 . The oral vaccine that comprises three strains of attenuated enterotoxigenic E. coli (ETEC) bacteria is in Phase...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Cambridge Biostability, National Institutes of Health drug delivery news

Cambridge Biostability disclosed a £119,000 ($233,000) grant it received from NIH last September to develop stable formulations of vaccines to prevent and treat malaria, tuberculosis and AIDS. Phase I testing of the malaria and TB...
08:00 , Dec 11, 2006 |  BC Week In Review  |  Company News

Cambridge Biostability, Panacea Biotec deal

Panacea received an exclusive license in India to Cambridge Biostability's stable liquid technology to develop and commercialize stable non-refrigerated versions of pentavalent and other combination vaccines for infectious diseases. Panacea also has non-exclusive rights to...
07:00 , Oct 23, 2006 |  BC Week In Review  |  Company News

Cambridge Biostability board of directors update

Cambridge Biostability Ltd. , Cambridge, U.K.   Business: Drug delivery   Appointed: John Lambert, a director, as chairman; he replaces David Stone, who will remain CEO  ...
07:00 , Apr 10, 2006 |  BC Week In Review  |  Company News

Ace BioSciences management update

Ace BioSciences A/S , Odense, Denmark   Business: Infectious, Antibodies   Hired: Michael Darsley as chief development officer, formerly director of vaccine development at Cambridge Biostability Ltd.  ...
00:25 , Apr 5, 2006 |  BC Extra  |  Company News

Ace names Darsley CDO

Infectious company Ace (Odense, Denmark) hired Michael Darsley as chief development officer. He was formerly director of vaccine development for Cambridge Biostability ( Cambridge , U.K.)....